Second-degree AV block Mobitz type I (Wenckebach) is a typically benign conduction disturbance at the level of the AV node, characterized by progressive PR prolongation before a dropped QRS complex. It generally carries an excellent prognosis and does not progress suddenly to complete heart block when the block is at the AV nodal level. [1-2] The following figure illustrates the classic Wenckebach pattern alongside other AV block types:
1. History
- Key HPI questions: Dizziness, lightheadedness, presyncope, syncope, exercise intolerance, fatigue, palpitations (sensation of "skipped beats")
- Symptom characterization: Intermittent vs. persistent; positional; relationship to exertion vs. rest/sleep
- Timing/triggers: Nocturnal occurrence (common and often benign), during exercise (concerning for infranodal disease), post-medication changes
- Associated symptoms: Chest pain, dyspnea, diaphoresis (consider ischemia); tick exposure or rash (Lyme); recent cardiac surgery or catheterization
- Important negatives: No syncope, no exertional symptoms, no chest pain, no recent medication changes [2]
2. Alarm Features
- Hemodynamic instability: Hypotension, altered mental status, signs of shock
- Wide QRS complex on ECG — suggests possible infranodal block despite Wenckebach pattern [1][4]
- Worsening AV conduction with exercise (block persists or worsens rather than improving) — suggests infranodal disease [2]
- Progression to higher-degree block: New Mobitz II pattern, high-grade AV block, or complete heart block
- Coexisting bundle branch block or alternating bundle branch block [1][5]
- Symptoms temporally correlated with documented bradycardia (syncope, presyncope)
- Acute MI setting — particularly inferior STEMI with new AV block [2]
- Neuromuscular disease (myotonic dystrophy, Kearns-Sayre) — risk of unpredictable progression [1][6]
3. Medications
Causative/contributing medications:
- Beta-blockers, non-dihydropyridine calcium channel blockers (verapamil, diltiazem), digoxin — most common iatrogenic causes [1][7]
- Antiarrhythmic drugs (amiodarone, flecainide, sotalol)
- Cholinesterase inhibitors (donepezil, neostigmine, pyridostigmine)
- Fingolimod, clonidine, ivabradine [7]
Acute treatment of symptomatic bradycardia:
- Atropine 0.5–1 mg IV every 3–5 min (max 3 mg) — first-line for AV nodal block [1-2]
- Dopamine 5–20 mcg/kg/min IV if atropine fails [1-2]
- Epinephrine 2–10 mcg/min IV infusion [1]
- Isoproterenol 1–20 mcg/min IV infusion (avoid if coronary ischemia suspected) [1]
- Aminophylline 250 mg IV bolus — specifically in acute inferior MI setting [1-2]
Contraindications/cautions:
- Atropine should NOT be used in heart transplant patients without autonomic reinnervation (risk of paradoxical block or sinus arrest) [1]
- Atropine should be used judiciously with wide QRS — may worsen infranodal block [1-2]
- Avoid adding additional AV nodal blocking agents in the acute setting
4. Diet
- No specific dietary triggers or restrictions for Mobitz I AV block
- In the setting of hyperkalemia-induced conduction disturbance, restrict potassium intake and correct electrolytes urgently
- Maintain adequate hydration — dehydration can exacerbate vagal tone and bradycardia
- Caffeine in moderation is generally not contraindicated
5. Review of Systems
- Cardiovascular: Palpitations, chest pain, dyspnea on exertion, orthopnea, edema (assess for structural heart disease)
- Neurologic: Syncope, presyncope, dizziness, seizure-like activity (from cerebral hypoperfusion)
- Constitutional: Fatigue, exercise intolerance, malaise
- Infectious: Fever, rash (erythema migrans), arthralgias, tick exposure (Lyme carditis) [2]
- Musculoskeletal: Myopathy, weakness (neuromuscular disease screening)
- Endocrine: Cold intolerance, weight gain, constipation (hypothyroidism)
6. Collateral History and Family History
- Collateral: Witnessed syncope or seizure-like episodes; medication compliance; recent medication changes; substance use
- Family history: Conduction system disease, pacemaker implantation, sudden cardiac death, cardiomyopathy, neuromuscular disease (myotonic dystrophy), congenital heart block [8]
- Social context: Athletic training history (endurance sports), occupation (risk if syncope occurs), tick-endemic area residence [5][9]
7. Risk Factors
- Increased vagal tone: Athletes, young healthy individuals, during sleep — typically benign [9-10]
- Advanced age with degenerative conduction system disease — most common acquired cause [2]
- Chronic hypertension and diabetes mellitus [2]
- Ischemic heart disease — particularly inferior MI (RCA supplies AV node in ~85% of patients) [2]
- Medications: Beta-blockers, CCBs, digoxin, antiarrhythmics [1][7]
- Infections: Lyme disease (endemic areas), rheumatic fever, endocarditis, myocarditis [2]
- Infiltrative/inflammatory: Cardiac sarcoidosis, amyloidosis, SLE, RA [1]
- Post-procedural: Catheter ablation, cardiac surgery (especially valve surgery), TAVR [1]
- Neuromuscular diseases: Myotonic dystrophy, Kearns-Sayre syndrome [1]
8. Differential Diagnosis
- Mobitz Type II AV block — critical to distinguish; fixed PR before dropped beat, wide QRS, infranodal, requires pacing. The key differentiator is the absence of progressive PR prolongation [1][10]
- 2:1 AV block — cannot be classified as Mobitz I or II from a single strip; requires additional evaluation to determine level of block [1-2]
- High-grade/advanced AV block — ≥2 consecutive non-conducted P waves [1]
- Complete (third-degree) AV block — complete AV dissociation
- Non-conducted PACs — mimics dropped beats; look for premature P waves deforming the T wave
- Sinus node dysfunction with sinus pauses — no preceding PR prolongation pattern
- Vagally mediated AV block — typically nocturnal, with concurrent sinus slowing [2]
9. Past Medical History
- Prior episodes of bradycardia, syncope, or documented AV block
- History of myocardial infarction (especially inferior)
- Structural heart disease, cardiomyopathy, valvular disease
- Prior cardiac surgery, catheter ablation, or TAVR [1]
- Lyme disease or other infectious myocarditis
- Neuromuscular disease
- Hypothyroidism, sleep apnea [2]
- Chronic use of AV nodal blocking medications
10. Physical Exam
Vital signs:
- Bradycardia (may be intermittent); assess for hypotension
- Irregular pulse with "group beating" pattern (classic for Wenckebach)
Focused exam:
- Cardiovascular: Irregular rhythm with periodic pauses; variable S1 intensity (due to changing PR interval); cannon A waves in JVP during dropped beats; murmurs (structural disease)
- Neurologic: Mental status, focal deficits (if syncope history)
- Skin: Erythema migrans rash (Lyme), signs of hypothyroidism
- Musculoskeletal: Myotonia, muscle wasting (neuromuscular disease)
11. Lab Studies
Recommended labs:
- BMP/CMP: Potassium, calcium, magnesium (electrolyte-induced conduction disturbance)
- TSH: Rule out hypothyroidism
- Digoxin level (if applicable)
- Lyme serologies (ELISA + Western blot) in endemic areas or with clinical suspicion [2]
- Troponin: If concern for acute coronary syndrome
Additional labs as indicated:
- ACE level, inflammatory markers (if sarcoidosis suspected)
- Drug levels for antiarrhythmics
- BNP/NT-proBNP if heart failure suspected
12. Imaging
- Echocardiogram — first-line to assess for structural heart disease, LV function, valvular disease [5]
- Chest X-ray — cardiomegaly, pulmonary congestion
- Cardiac MRI — if infiltrative disease suspected (sarcoidosis, amyloidosis)
- Coronary angiography/CT angiography — if ischemic etiology suspected
When imaging is unnecessary: Asymptomatic young athletes with Wenckebach that resolves with exercise and no other concerning features may not require advanced imaging beyond echocardiography [8]
13. Special Tests
- Ambulatory ECG monitoring (Holter 24–48h, event monitor 30–90 days, or implantable loop recorder >2 years) — to correlate symptoms with rhythm; event monitors and loop recorders have greater diagnostic yield than short-term Holter [1-2]
- Exercise stress test — improvement in AV conduction with exercise suggests AV nodal block (benign); worsening conduction suggests infranodal disease (concerning) [2]
- Electrophysiology study (EPS) — may be considered in selected patients to determine level of block (intra-His vs. infra-His); HV interval >100 ms suggests infranodal disease warranting pacing [2][4]
- Pharmacologic challenge: Atropine (improves AV nodal block), isoproterenol, or procainamide may help localize the level of block [2]
14. ECG
Classic ECG findings:
- Progressive PR prolongation with each successive beat until a P wave is not conducted (dropped QRS)
- Group beating pattern — clusters of conducted beats separated by pauses
- Shortening of RR intervals before the dropped beat (due to decreasing increments of PR prolongation)
- Narrow QRS (typically) — suggests AV nodal level block [1][10]
- The longest PR interval is the beat immediately before the drop; the shortest PR is the beat immediately after the drop
Concerning ECG patterns:
- Wide QRS (>120 ms) — may indicate infranodal block even with Wenckebach pattern [1]
- Bundle branch block or bifascicular block coexisting with Wenckebach [5]
- 2:1 conduction — cannot classify as Mobitz I vs. II; requires further workup [1]
- Atypical Wenckebach patterns (non-classic PR increment patterns) are common and do not change management [3]
15. Assessment
Clinical summary: Mobitz type I (Wenckebach) is generally benign when the block is at the AV nodal level, particularly in young patients, athletes, and during sleep. [1][10] It does not typically progress suddenly to complete heart block. The critical clinical decision is determining whether the block is AV nodal vs. infranodal, as infranodal Wenckebach carries a significantly worse prognosis and may require pacing even without symptoms. [1-2]
Severity stratification:
- Benign: Asymptomatic, narrow QRS, improves with exercise, young/athletic patient
- Intermediate: Symptomatic but hemodynamically stable; unclear symptom-rhythm correlation
- High-risk: Wide QRS, worsens with exercise, coexisting bundle branch block, hemodynamic compromise, acute MI setting
Complications: Hemodynamic compromise from loss of AV synchrony (especially with frequent dropped beats), progression to higher-degree block (rare at AV nodal level), syncope-related injury [2][4]
16. Treatment Plan
Asymptomatic patients:
- No treatment required in most cases — per ACC/AHA/HRS 2018 guidelines, permanent pacing should not be performed in asymptomatic patients with Mobitz I at the AV nodal level (Class III: Harm) [2]
- Discontinue or reduce offending medications if possible
- Treat reversible causes (Lyme disease, electrolyte abnormalities, hypothyroidism) [2]
Symptomatic patients (acute):
- Atropine 0.5–1 mg IV q3–5 min (max 3 mg) — first-line [1-2]
- Transcutaneous pacing if atropine fails and hemodynamically unstable [11]
- Dopamine 5–20 mcg/kg/min or epinephrine 2–10 mcg/min as bridge [1]
- Temporary transvenous pacing for refractory cases
Chronic symptomatic patients:
- Permanent pacemaker — indicated when symptoms clearly correlate temporally with the AV block and affect quality of life [1-2]
- Ambulatory monitoring or exercise testing to establish symptom-rhythm correlation [2]
The following algorithm from the 2018 ACC/AHA/HRS guidelines outlines the management approach for chronic AV block:
17. Disposition
Discharge criteria:
- Asymptomatic with narrow QRS and no hemodynamic compromise
- Known Wenckebach in an athlete or during sleep with no red flags
- Reversible cause identified and treated (e.g., medication adjusted)
- Stable vital signs, no syncope
Observation/admission criteria:
- Symptomatic bradycardia requiring treatment
- New-onset Wenckebach in the setting of acute MI
- Unclear whether block is Mobitz I vs. Mobitz II
- Wide QRS or coexisting bundle branch block
- Hemodynamic instability
Specialist consultation triggers:
- Cardiology/electrophysiology referral for symptomatic patients, wide QRS, exercise-induced worsening, or need for EPS [2]
- Infectious disease if Lyme carditis suspected [2]
18. Follow Up / Return Precautions
Follow-up timing:
- Asymptomatic: Outpatient cardiology follow-up within 1–4 weeks with ambulatory monitoring if symptoms are intermittent [2]
- Post-discharge after symptomatic episode: Close follow-up within 1 week
Symptoms requiring immediate reassessment:
- Syncope or near-syncope
- New or worsening dizziness, lightheadedness, or exercise intolerance
- Chest pain or dyspnea
- Prolonged pauses or palpitations
Patient counseling points:
- Wenckebach is usually benign and does not typically require a pacemaker unless symptoms are clearly linked to the rhythm [1-2]
- Avoid abrupt discontinuation of prescribed medications without physician guidance
- Report any new symptoms promptly
- Athletes: Can participate in all competitive sports if asymptomatic with structurally normal heart and conduction improves with exercise [5][8][13]
Expected recovery course: If due to a reversible cause (medication, Lyme disease, inferior MI), AV block typically resolves within days to weeks with appropriate treatment. [2] Idiopathic or degenerative Wenckebach may persist but rarely progresses to higher-degree block when at the AV nodal level. [1][4]
References
1. 2018 ACC/AHA/HRS Guideline on The Evaluation and Management Of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Kusumoto FM, Schoenfeld MH, Barrett C, et al. Journal of the American College of Cardiology. 2019.
2. 2018 ACC/AHA/HRS Guideline on The Evaluation and Management Of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Kusumoto FM, Schoenfeld MH, Barrett C, et al. Journal of the American College of Cardiology. 2019.
3. 2018 ACC/AHA/HRS Guideline on The Evaluation and Management Of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Kusumoto FM, Schoenfeld MH, Barrett C, et al. Journal of the American College of Cardiology. 2019.
4. 2018 ACC/AHA/HRS Guideline on The evaluation and Management Of patients With Bradycardia and Cardiac conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Writing Committee Members, Kusumoto FM, Schoenfeld MH, et al. Heart Rhythm. 2019.
5. 2018 ACC/AHA/HRS Guideline on The evaluation and Management Of patients With Bradycardia and Cardiac conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. — Writing Committee Members, Kusumoto FM, Schoenfeld MH, et al. Heart Rhythm. 2019.
6. Mechanisms, Classification, and Clinical Aspects of Arrhythmias. — Antoni Bayés De Luna, Miquel Fiol‐Sala, Antoni Bayés‐Genís, et al. Clinical Electrocardiography. 2021.
7. Mechanisms, Classification, and Clinical Aspects of Arrhythmias. — Antoni Bayés De Luna, Miquel Fiol‐Sala, Antoni Bayés‐Genís, et al. Clinical Electrocardiography. 2021.
8. 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. — Epstein AE, DiMarco JP, Ellenbogen KA, et al. Journal of the American College of Cardiology. 2013.
9. 2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. — Epstein AE, DiMarco JP, Ellenbogen KA, et al. Journal of the American College of Cardiology. 2013.
10. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. — Zipes DP, Link MS, Ackerman MJ, et al. Circulation. 2015.
11. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 9: Arrhythmias and Conduction Defects: A Scientific Statement From the American Heart Association and American College of Cardiology. — Zipes DP, Link MS, Ackerman MJ, et al. Circulation. 2015.
12. Cardiac Pacemakers: Function, Troubleshooting, and Management: Part 1 of a 2-Part Series. — Mulpuru SK, Madhavan M, McLeod CJ, Cha YM, Friedman PA. Journal of the American College of Cardiology. 2017.
13. Cardiac Pacemakers: Function, Troubleshooting, and Management: Part 1 of a 2-Part Series. — Mulpuru SK, Madhavan M, McLeod CJ, Cha YM, Friedman PA. Journal of the American College of Cardiology. 2017.
14. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. — Tisdale JE, Chung MK, Campbell KB, et al. Circulation. 2020.
15. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. — Tisdale JE, Chung MK, Campbell KB, et al. Circulation. 2020.
16. 2024 HRS Expert Consensus Statement on Arrhythmias in the Athlete: Evaluation, Treatment, and Return to Play. — Lampert R, Chung EH, Ackerman MJ, et al. Heart Rhythm. 2024.
17. 2024 HRS Expert Consensus Statement on Arrhythmias in the Athlete: Evaluation, Treatment, and Return to Play. — Lampert R, Chung EH, Ackerman MJ, et al. Heart Rhythm. 2024.
18. Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology. — Eijsvogels TMH, Kim JH, Aengevaeren VL, et al. Journal of the American College of Cardiology. 2026.
19. Masters Athletes With Abnormal Cardiovascular Findings: A Clinical Consensus Statement of the European Association of Preventive Cardiology of the ESC and the American College of Cardiology. — Eijsvogels TMH, Kim JH, Aengevaeren VL, et al. Journal of the American College of Cardiology. 2026.
20. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.
21. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings: A Scientific Statement From the American Heart Association. — Sandau KE, Funk M, Auerbach A, et al. Circulation. 2017.
22. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Panchal AR, Bartos JA, Cabañas JG, et al. Circulation. 2020.
23. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. — Panchal AR, Bartos JA, Cabañas JG, et al. Circulation. 2020.
24. 2018 ACC/AHA/HRS Guideline on The Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. — Kusumoto FM, Schoenfeld MH, Barrett C, et al. Journal of the American College of Cardiology. 2019.
25. 2018 ACC/AHA/HRS Guideline on The Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, and the Heart Rhythm Society. — Kusumoto FM, Schoenfeld MH, Barrett C, et al. Journal of the American College of Cardiology. 2019.
26. Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology. — Kim JH, Baggish AL, Levine BD, et al. Circulation. 2025.
27. Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology. — Kim JH, Baggish AL, Levine BD, et al. Circulation. 2025.